JPS5599189A - Modified uricase free from antigenicity and its preparation - Google Patents

Modified uricase free from antigenicity and its preparation

Info

Publication number
JPS5599189A
JPS5599189A JP578779A JP578779A JPS5599189A JP S5599189 A JPS5599189 A JP S5599189A JP 578779 A JP578779 A JP 578779A JP 578779 A JP578779 A JP 578779A JP S5599189 A JPS5599189 A JP S5599189A
Authority
JP
Japan
Prior art keywords
uricase
antigenicity
preparation
free
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP578779A
Other languages
Japanese (ja)
Inventor
Yuji Inada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MIHAMA HISAHARU
Original Assignee
MIHAMA HISAHARU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MIHAMA HISAHARU filed Critical MIHAMA HISAHARU
Priority to JP578779A priority Critical patent/JPS5599189A/en
Publication of JPS5599189A publication Critical patent/JPS5599189A/en
Pending legal-status Critical Current

Links

Landscapes

  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PURPOSE: To prepare a modified uricase usable for treating patients with hyperuricemia, having a low or no antigenicity, by substituting 30% or more of amino groups in the uricase molecule with long-chain high polymer residues.
CONSTITUTION: Uricase is reacted with an 2-O-substituted-polyethylene glycol-4, 6-dichloro-s-triazine, e.g. 2-O-methoxypolyethylene glycol-4,6-dichloro-s-triazine, having a molecular weight ≥2,000 to give a modified uricase wherein 30% or more of amino groups in the uricase molecule are substituted by groups of the formula (R is water-soluble high polymer residue, e.g. O-methoxypolyethylene glycol residue, having a molecular weight ≥2,000).
COPYRIGHT: (C)1980,JPO&Japio
JP578779A 1979-01-22 1979-01-22 Modified uricase free from antigenicity and its preparation Pending JPS5599189A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP578779A JPS5599189A (en) 1979-01-22 1979-01-22 Modified uricase free from antigenicity and its preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP578779A JPS5599189A (en) 1979-01-22 1979-01-22 Modified uricase free from antigenicity and its preparation

Publications (1)

Publication Number Publication Date
JPS5599189A true JPS5599189A (en) 1980-07-28

Family

ID=11620804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP578779A Pending JPS5599189A (en) 1979-01-22 1979-01-22 Modified uricase free from antigenicity and its preparation

Country Status (1)

Country Link
JP (1) JPS5599189A (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57192435A (en) * 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
WO2006110819A2 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
US7229810B2 (en) 2001-06-28 2007-06-12 Mountain View Pharmaceuticals, Inc. Polymer conjugates of proteinases
EP2158923A1 (en) 1998-08-06 2010-03-03 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US7811800B2 (en) 2005-04-11 2010-10-12 Savient Pharmaceuticals, Inc. Variant form of urate oxidase and use thereof
US7927852B2 (en) 1998-08-06 2011-04-19 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
EP2535347A1 (en) 2002-09-30 2012-12-19 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US9534013B2 (en) 2006-04-12 2017-01-03 Horizon Pharma Rheumatology Llc Purification of proteins with cationic surfactant
US11598767B2 (en) 2009-06-25 2023-03-07 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
JP2023548496A (en) * 2020-11-03 2023-11-17 プロタリクス リミテッド Modified uricase and its use
US12465631B2 (en) 2019-01-30 2025-11-11 Horizon Therapeutics Usa, Inc. Reducing immunogenicity to pegloticase
US12496331B2 (en) 2016-11-11 2025-12-16 Horizon Therapeutics Usa, Inc. Combination therapies of prednisone and uricase molecules and uses thereof

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57192435A (en) * 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
US9885024B2 (en) 1998-08-06 2018-02-06 Duke University PEG-urate oxidase conjugates and use thereof
EP2158923A1 (en) 1998-08-06 2010-03-03 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US8921064B2 (en) 1998-08-06 2014-12-30 Mountain View Pharmaceuticals, Inc. Method for purifying urate oxidase tetramers and octamers
US7927852B2 (en) 1998-08-06 2011-04-19 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US7927589B2 (en) 1998-08-06 2011-04-19 Mountain View Pharmaceuticals, Inc. PEG-urate oxidase conjugates and use thereof
EP2316475A1 (en) 1998-08-06 2011-05-04 Mountain View Pharmaceuticals, Inc. Isolated tetrameric uricase
US8618267B2 (en) 1998-08-06 2013-12-31 Mountain View Pharmaceuticals, Inc. PEG-urate oxidase conjugates and use thereof
US8067553B2 (en) 1998-08-06 2011-11-29 Mountain View Pharmaceuticals, Inc. PEG-urate oxidase conjugates and use thereof
US7229810B2 (en) 2001-06-28 2007-06-12 Mountain View Pharmaceuticals, Inc. Polymer conjugates of proteinases
EP2535347A1 (en) 2002-09-30 2012-12-19 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8541205B2 (en) 2005-04-11 2013-09-24 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
US7964381B2 (en) 2005-04-11 2011-06-21 Savient Pharmaceuticals, Inc. Variant form of urate oxidase and use thereof
US8188224B2 (en) 2005-04-11 2012-05-29 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
US8293228B2 (en) 2005-04-11 2012-10-23 Savient Pharmaceuticals Inc. Variant form of urate oxidase and use thereof
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US8465735B2 (en) 2005-04-11 2013-06-18 Savient Pharmaceuticals, Inc. Variant form of urate oxidase and use thereof
US8034594B2 (en) 2005-04-11 2011-10-11 Savient Pharmaceuticals, Inc. Variant form of urate oxidase and use thereof
US11781119B2 (en) 2005-04-11 2023-10-10 Horizon Therapeutics Usa, Inc. Variant forms of urate oxidase and use thereof
US7811800B2 (en) 2005-04-11 2010-10-12 Savient Pharmaceuticals, Inc. Variant form of urate oxidase and use thereof
US9017980B2 (en) 2005-04-11 2015-04-28 Crealta Pharmaceuticals Llc Variant forms of urate oxidase and use thereof
EP2947145A1 (en) 2005-04-11 2015-11-25 Crealta Pharmaceuticals LLC Variant forms of urate oxidase and use thereof
US8178334B2 (en) 2005-04-11 2012-05-15 Savient Pharmaceuticals, Inc. Variant form of urate oxidase and use thereof
US9670467B2 (en) 2005-04-11 2017-06-06 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
WO2006110819A2 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
EP3321359A1 (en) 2005-04-11 2018-05-16 Crealta Pharmaceuticals LLC Variant forms of urate oxidase and use thereof
US9534013B2 (en) 2006-04-12 2017-01-03 Horizon Pharma Rheumatology Llc Purification of proteins with cationic surfactant
US11639927B2 (en) 2009-06-25 2023-05-02 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US11598767B2 (en) 2009-06-25 2023-03-07 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US11982670B2 (en) 2009-06-25 2024-05-14 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US12188927B2 (en) 2009-06-25 2025-01-07 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US12560596B2 (en) 2009-06-25 2026-02-24 Amgen Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US12496331B2 (en) 2016-11-11 2025-12-16 Horizon Therapeutics Usa, Inc. Combination therapies of prednisone and uricase molecules and uses thereof
US12465631B2 (en) 2019-01-30 2025-11-11 Horizon Therapeutics Usa, Inc. Reducing immunogenicity to pegloticase
JP2023548496A (en) * 2020-11-03 2023-11-17 プロタリクス リミテッド Modified uricase and its use

Similar Documents

Publication Publication Date Title
JPS5599189A (en) Modified uricase free from antigenicity and its preparation
EP0310321A3 (en) Immunomodulatory azaspiranes
MD1233B1 (en) Erythromycin derivatives, process for their preparation and pharmaceutical composition on base thereof
JPS55138393A (en) Semisynthesis of insulin
PT79840A (en) Process for the preparation of polipeptides with alpha-amilase inhibiting action and pharmaceutical compositions therewith
YU89691A (en) PROCEDURE FOR OBTAINING STEREOSELECTIVE DERIVATIVES OF PHENYLISOSERIN
AU3923789A (en) Diorganopolysiloxane derivatives, their preparation and their use
ES8103027A1 (en) Tripeptides, process for their preparation, therapeutic compositions containing them and methods for their use.
DK109180A (en) PEPTIDES WITH UBIQUITIN SIMILAR ACTIVITY AND PROCEDURE FOR PREPARING THEREOF
ES2008962A6 (en) New-quanidino-thiazol compounds, their preparation, and use as intermediates of famotidine process.
JPS55135590A (en) Modified asparaginase and uricase and their preparation
JPS5219754A (en) Preparation of crosslinked epihalohydrin polymer composition
UA41871C2 (en) Derivatives of erythromycin, a process for the preparation thereof and a pharmaceutical composition based thereon
ES2001389A6 (en) Substituted toluidines, process for their preparation, pharmaceutical compositions containing them and their use as gastric secretion inhibitors.
IL94703A0 (en) Thienopyran derivatives,their preparation and pharmaceutical compositions containing them
LTIP577A (en) Novel pilocarpine derivatives and process for their preparation
DE3361628D1 (en) Substituted 5-phenylthio-6-amino-pyrimidinones, process for their preparation and their use, and preparations containing these compounds
JPS5559151A (en) Aminoacid derivative
JPS55138392A (en) Semisynthesis of insulin
AU4915090A (en) Cycloaminoalkoxyphenyl derivatives, a process for their preparation as well as the compositions containing them
JPS5440894A (en) Cinchona-alkaloid-acrylonitrile copolymer and its preparation
JPS5283737A (en) Novel carboxylic acid amide derivatives and preparation thereof
JPS5236185A (en) Preparation of novel reactive polymer
JPS54106481A (en) Novel 2,3-dioxopiperazine derivative and its preparation
JPS5371093A (en) Benzothiepin derivs. and process for their preparation